Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.23, Zacks reports. Vivos Therapeutics had a negative net margin of 107.36% and a negative return on equity of 2,325.64%. The business had revenue of $6.41 million for the quarter, compared to analyst estimates of $5.47 million.
Here are the key takeaways from Vivos Therapeutics’ conference call:
- Revenue fell 5% year over year to $6.4 million in Q3, and gross margin declined to 52% from 58%, partly reflecting lower product sales as Vivos shifts away from VIPs. For the first nine months, revenue and gross profit each rose 23%, driven by 57% growth in service revenue.
- Cost reductions helped narrow Q3 operating loss by 18% to $3.9 million, while general and administrative and sales and marketing expenses together fell $1.6 million year over year. Net loss improved to $2.0 million, though that result included a one-time benefit of about $2.9 million from reversing an Employee Retention Credit liability.
- Management said monthly new-patient referrals to its two Nevada treatment centers have nearly quadrupled since May and expects payer renegotiations to potentially add about $3.8 million in annual revenue, before any increase in patient volume. It also expects new clinical services and payer initiatives to contribute more in Q4 and 2027, but those outcomes depend on execution, reimbursement, and patient participation.
- Liquidity remains a major risk: Vivos had about $0.2 million in cash at quarter-end, used $12.3 million in operating cash in the first nine months, and said it needs additional financing. The company warned that without financing there is substantial doubt about its ability to continue as a going concern.
- Vivos remains out of compliance with Nasdaq’s $1 minimum bid-price requirement, with a compliance deadline of December 4, 2026; the company said its shares have recently traded below $0.10, which could trigger suspension and delisting proceedings. Stockholders are scheduled to vote on a proposed reverse stock split intended to address the bid-price issue.
Vivos Therapeutics Stock Performance
NASDAQ VVOS opened at $0.08 on Wednesday. The firm has a market capitalization of $1.60 million, a price-to-earnings ratio of -0.05 and a beta of 6.37. Vivos Therapeutics has a one year low of $0.07 and a one year high of $2.69. The company’s 50 day moving average price is $0.14 and its 200 day moving average price is $0.65.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vivos Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $2.80.
Read Our Latest Report on Vivos Therapeutics
Vivos Therapeutics Company Profile
Vivos Therapeutics is a medical technology company focused on treatments for sleep-disordered breathing, including obstructive sleep apnea. The company works with dental providers to offer non-surgical approaches intended to improve patients’ airways and breathing during sleep. Its Vivos System combines proprietary oral appliances with treatment protocols used by trained dental professionals. The company also provides education and support to providers who offer its therapies. Based in Littleton, Colorado, Vivos primarily serves patients through a network of participating dental practices.
Read More
- Five stocks we like better than Vivos Therapeutics
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
